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Renal vascular response to interruption of the renin-angiotensin
system in normal man. We assessed the role of the renin-angiotensin
system in the response of the renal circulation to restriction of
sodium intake in 38 normal patients. Both saralasin (10 to 30
ng/kg/min), an angiotensin antagonist, and SQ 20881 (30 to
300ig/kg), a converting enzyme inhibitor, induced a dose-related
increase in renal blood flow (xenon 133 washout) only when the
renin-angiotensin system was activated by restriction of sodium
intake to 10 mEq/day. Increasing doses of saralasin (100 to 1,000
ng/kg/min) reduced renal blood flow, presumably due to the
angiotensin-like action of this partial agonist. The renal vascular
response to SQ 20881 paralleled the endocrine response: An identi-
cal threshold dose (30tg/kg) increased renal blood flow and re-
duced plasma angiotensin II concentration, which fell despite a
progressive rise of plasma renin activity. Plasma bradykinin con-
centration did not change in response to SQ 20881, which also
blocks kininase II. Both agents also induced a small but consistent
and statistically significant reduction in arterial blood pressure,
which will be important in assessing the pathogenetic significance
of a blood pressure reduction in patients with hypertension. This
study indicates that angiotensin mediates the renal vascular re-
sponse to restriction of salt intake in normal man and provides an
approach to assessing the role played by angiotensin in the patho-
genesis of functional renal disease.
Réponse vasculaire du rein a l'interruption du système rénine-
angiotensine chez I'homme normal. Nous avons évalué le role du
système rénine-angiotensine dans Ia réponse de Ia circulation ré-
nale a Ia restriction de l'apport de sodium chez 38 sujets nor-
maux. La saralasine (10 a 30 ng/kg/min), un antagoniste de
l'angiotensine, de même que Ic SQ 20881 (30 a 300 pg/kg), un
inhibiteur de l'enzyme de conversion, déterminent une augmenta-
tion du debit sanguin renal (lavage au 133Xe) proportionnelle a Ia
dose, mais seulement quand l'apport alimentaire est réduitjusqu'à
10 mEq/jour. L'augmentation des doses de saralasine (100 a 1,000
ng/kg/min) diminue Ic debit sanguin renal, probablement du fait
de l'action de type angiotensine de cet agoniste partiel. La réponse
vasculaire rénale au SQ 20881 est parallèle a Ia réponse endo-
crinienne: une dose seuil identique (30kg/kg) augmente Ic debit
sanguin renal et diminue Ia concentration plasmatique
d'angiotensine, qui décroit malgré une augmentation progressive
de I'activité refine plasmatique. La concentration plasmatique de
bradykinine ne change pas lors de l'administration de SQ 20881,
qui bloque aussi Ia kininase II. Les deux agents étudiés déterminent
une diminution faible, mais significative, de Ia pression artCrielle.
Ce fait sera important dans l'évaluation de Ia signification patho-
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génique d'une diminution de Ia pression artCrielle chez des malades
atteints d'hypertension. Ce travail montre que l'angiotensine est un
mCdiateur de Ia réponse vasculaire rénale a Ia restriction de
l'apport de sodium chez I'homme, et il fournit une approche de
I'évaluation du role de l'angiotensine dans Ia pathogenic des altéra-
tions fonctionnelles du rein.
Interest in the renin-angiotensin system has fo-
cused primarily on defining either its contribution to
the pathogenesis of hypertension, on the one hand, or
to sodium homeostasis via aldosterone-release, on
the other. Stimuli to renin-release [1, 2], such as
restriction of sodium intake, frequently have been
also associated with a reduction in renal blood flow
[3—5]. The mechanisms responsible for the reduction
in renal blood flow induced by a restriction of sodium
intake in man have not been defined; earlier sugges-
tions that the renal yascular response reflected activa-
tion of the sympathetic nervous system via alpha
receptors [6—8] have not been borne out [9, 10]. In
view of the striking sensitivity of the renal vasculature
to angiotensin [II], this powerful vasoconstrictor
agent represents an alternative candidate as a media-
tor.
Pharmacologic interruption of the renin-angioten-
sin system provides an approach to assessing angio-
tensin's role in the renal vascular response. Angioten-
sin antagonists or agents which block conversion of
angiotensin I to angiotensin II have induced an in-
crease in renal blood flow in animals in which the
system was activated by a variety of maneuvers
[12—20], but not when the system was suppressed.
In this study, the role of angiotensin 'was examined
in normal man by assessing the renal vascular re-
sponse to pharmacologic interruption of the renin-
angiotensin system after its activation by a restricted
salt intake. Because each of the agents has a com-
plicated pharmacology, we used two classes of
agents, a competitive antagonist to angiotensin H and
a converting enzyme inhibitor, and we examined the
endocrine responses to each agent. These studies pro-
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vide insight into the control of the renal circulation in
normal man and an approach to assessing the role
played by angiotensin in the pathogenesis of renal
disease.
Methods
Subjects. Studies were carried out in 38 normal,
potential kidney donors at the time of selective renal
arterial catheterization for arteriography. Each pa-
tient, ranging in age from 18 to 63 yr, received a
careful evaluation with special emphasis on cardio-
vascular, renal, and adrenal status [10, 11]. They were
admitted to a metabolic ward and placed on a diet
which provided a daily intake of either 10 or 200 mEq
of sodium and 100 mEq of potassium for at least five
days prior to study. Balance was assessed by mea-
surements of sodium excretion in 24-hr urine collec-
tions, by a detailed assessment of daily dietetic in-
take, and by serial weight measurements.
Techniques. Percutaneous selective renal arterial
catheterization, the determination of renal blood
flow with radioactive xenon (133Xe) and external
probe counting, and cardiovascular monitoring dur-
ing the administration of vasoactive agents have been
described in detail [10, 11]. The catheter was used for
the continuous monitoring of blood pressure and
heart rate, for injecting '33Xe, and for drawing arte-
rial blood samples for measurements of electrolytes
and hormones. Blood pressure was measured with a
transducer (Statham P23 dB) and recorded continu-
ously along with the instantaneous pulse rate and the
electrocardiogram. Continuous monitoring insured
patient safety and cardiovascular stability, and made
it possible to measure the small blood pressure
changes which occurred with these agents. Three pa-
tients were potential donors to small children, and
they also had renal venography, making it possible to
obtain renal venous blood samples for assay of
plasma renin activity and plasma angiotensin and
bradykinin concentrations.
The study was initiated at least 30 mm after blood
pressure stability had been achieved following
aortography. A control blood flow determination
was obtained, and a control arterial blood sample
was drawn for the measurement of plasma renin ac-
tivity (PRA), angiotensin II (All), bradykinin, so-
dium, and potassium concentrations. Then, either the
antagonist analogue saralasin acetate (P1 13; 1-Sar, 8-
Ala angiotensin II, Norwich Pharmacal Co.) or the
converting enzyme inhibitor SQ 20881 (Squibb Phar-
maceutical Co.) was administered. Nineteen patients
received each agent.
Saralasin was infused i.v. with a motor-driven
pump (Harvard Apparatus Company, Millis, MA) in
5% glucose and water, diluted to allow administra-
tion of the agent at 0.3 to 1.9 mI/mm. SQ 20881 was
administered either i.v. or into the renal artery as a
bolus over about 60 sec.
Protocols. i) Saralasin dose-response curve: In nine
patients in balance on a low salt diet, we established
the relationship between the saralasin doses adminis-
tered in graded logarithmic increments from 10 to
1,000 ng/kg of body wt per mm and the blood pres-
sure .and renal vascular response. Two to four doses
infused for at least six minutes were administered to
each patient, and the renal vascular response was
determined after three minutes. Each dose was as-
sessed in at least four individuals. In six additional
patients, a single dose of 30 ng/kg/min was infused
continuously for 40 mm to assess the time course of
the renal vascular, blood pressure, and renin respon-
ses.
ii) Four patients in balance on a 200 mEq sodium
intake were studied with an identical protocol, to
supplement earlier observations on the renal vascular
response to saralasin in this state [21]. Because doses
below 100 ng/kg/min were not administered in the
earlier study, it was necessary to assess the responses
to 10 and 30 ng/kg/min, for comparison with respon-
ses to these doses on a low salt diet.
iii) An identical study was performed with SQ
20881 infused i.v. in doses ranging from 10 to 300
g/kg/min in 12 normal patients in balance on a low
salt diet. A 20-mm period was assessed at the top
dose used in each patient. An identical protocol was
used to assess these responses in four additional nor-
mal patients in balance on a 200 mEq sodium diet.
iv) In three normal patients in balance on a low salt
diet, an identical protocol was used, but the agent
was infused into the renal artery by way of a co-axial
catheter system, which we have described previously
[10]. Responses were assessed at 3 and 20 mm at each
dose.
Analytic Techniques. All blood samples were col-
lected in plastic syringes, placed on ice, spun immedi-
ately at 4°C, and the plasma frozen until time for
assay. The anticoagulant was ethylenediaminetetra-
acetate (EDTA) for bradykinin, PRA, and angio-
tensin II samples. Diisofluorophosphate was also
added to the samples for angiotensin II assay.
Samples for bradykinin measurement were col-
lected in prechilled polypropylene tubes containing
0.36 mg of polybrene (to inhibit Hageman factor and
thereby bradykinin generation) and 0.9 mg of EDTA
(to inhibit kininases and thereby bradykinin destruc-
tion). To precipitate proteins, 0.25 ml of 20% tn-
chloracetic acid was added to 5 ml of plasma. The
supernatant was chromatographed on an Amberlite
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CG-50 column, washed with 0.1 ml of acetic acid,
and taken for radioimmune assay with polyethylene
glycol to separate bound and free.
Angiotensin II was measured by a double-antibody
radioimmunoassay method [21]. Saralasin showed
0.07% cross-reactivity with the angiotensin antibody,
sufficient to interfere with angiotensin II measure-
ments following saralasin infusion. PRA was mea-
sured by radioimmunoassay of angiotensin I (A!)
generated during a 30-mm incubation with endog-
enous substrate at 37°C. No cross-reactivity was de-
monstrable between P113 and the angiotensin I anti-
body. The bradykinin assay was performed by
radioimmunoassay, as described by Talamo, Haber,
and Austen [221, and modified by the use of a differ-
ent antiserum raised in rabbits with an enhanced
sensitivity of 25 pg/reaction tube. Recovery was 90 to
105%. SQ 20881 did not cross-react with any anti-
body used in radioimmunoassay.
Creatinine concentration in urine and serum was
determined by the autoanalyzer method. Sodium and
potassium concentrations in urine and serum were
measured by flame photometry, with lithium as an
internal standard.
Mean renal blood flow was measured from the
initial slope of '33Xe disappearance from the kidney,
determined graphically, with a hematocrit-corrected
partition coefficient; compartmental analysis was also
performed. Curves reanalyzed on a coded basis
showed a coefficient of variation of 7% [23].
Group means were calculated with the standard
error of the mean (sEM) as the index of dispersion.
The evaluation of statistical probability (P) was car-
ried out, where appropriate, with the Student's I test
or paired data t test. Otherwise, the Wilcoxon rank
sum (WRST) or Fisher Exact test (FET) for non-
parametric data was used. The null hypothesis was
rejected when the P value was less than 0.05.
The protocol was approved by the Human Experi-
mentation Committees of the Peter Bent Brigham
Hospital and Harvard Medical School. Written per-
mission for the procedure was obtained from each
patient after a detailed description of the protocols.
Results
The relationships between saralasin doses infused
i.v. and changes in renal blood flow and blood pres-
sure three minutes after initiating each infusion are
summarized in Figure 1. Saralasin induced a small
(0.13 0.04 ml/g/min; P < 0.025) but statistically
significant increase in renal blood flow at the lowest
dose used, 10 ng/kg/min. Renal blood flow was in-
creased further, by a mean of 0.53 0.07 ml/g/min
at the 30 ng/kg/min dose (paired I = 7.25; P <<
0.001). Increasing doses, however, resulted in a pro-
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Fig. I. Change in mean arterial blood pressure (MBP) and mean
renal blood flow (MR BE) in normal patients who were studied while
on a sodium-restricted intake. Note the biphasic renal vascular
response.
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Fig. 2. Arterial pressure (MBP) and renal vascular response (MRBF)
in patients on a low salt diet (Fig. 1) are contrasted with patients
studied in balance on a high salt diet. Note that on a high salt diet
saralasin induced, a pressor response and did not increase renal
blood flow at any dose studied.
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gressive, dose-related, blood flow reduction, which
paralleled the renal vascular response in normal pa-
tients on a high salt diet (Fig. 2). The intrinsic activity
of saralasin with increasing dose was unequivocal in
both groups, but was considerably less in the patients
on a low sodium intake. In patients on a high salt
diet, no saralasin dose induced an increase in renal
blood flow. The increase in mean blood flow induced
by saralasin was associated with both a significant
increase in the flow rate in the rapid flow component
(4.4 0.3 vs. 5.2 0.3 ml/g/min; P < 0.01) and in
the percentage of flow entering that compartment
(74.4 3.2 vs. 81.8 3.1%; P < 0.01).
A small but consistent reduction in mean arterial
blood pressure was apparent in 12 of 15 patients on a
low salt diet at doses ranging from 10 to 100
ng/kg/min, but with increasing dosage, mean blood
pressure tended to return toward control. Only 4 of
20 normal patients on a high salt diet showed any
tendency for blood pressure to fall (P = 0.0005;
FET). The largest blood pressure change in the nor-
mal patients on a low salt diet averaged —5.6 1.09
mm Hg with a range of 0 to —14mm Hg, and with a
high salt diet, was +5.0 1.43 mm Hg.
The time course of the blood pressure and renal
vascular response to a continued saralasin infusion at
30 ng/kg/min in patients on a low salt diet is summa-
rized in Figure 3. Blood flow rose progressively to a
maximum increase of 0.48 0.11 ml/g/min, a 15%
increase, within 10 mm of initiating the infusion and
stabilized at that level for the following 30 mm. Blood
pressure fell progressively over 10 mm and stabi-
lized, with a mean reduction of —5 2 mm Hg (P <
0.01).
SQ 20881 at l0tg/kg/min, when administered i.v.,
did not modify renal blood flow significantly (Fig. 4).
An unequivocal flow increase occurred in association
with a 30tg/kg dose, and the flow response increased
only slightly with increasing dosage to 3OOtg/kg.
When serial determinations were made, a small but
significant increase in renal blood flow occurred over
the first 20 mm (P = 0.045) (Fig. 4). The maximum
increase in mean blood flow averaged 0.80 0.04
ml/g/min. In association with the increase in mean
blood flow, both the percentage of flow entering the
rapid component (71.9 1.9 vs. 82.2 1.4; P <
40 0.0001), and the rapid component flow rate (3.9 +
0.17 vs. 5.6 0.20 ml/g/min; P < 0.005) increased
significantly.
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Fig. 3. Time course of the response in norma/patients on a 10 mEq
sodium diet to saralasin (P1/3) infused iv. at 30 ng/kg/min for 40
mm: The time course of the renal vascular response is consistent
with known pharmacokinetics of saralasin, reaching a plateau
within 10 mm. +5
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Fig. 4. Effect of administering SQ 20881 iv. to block converting
enzyme in patients in balance on a low salt diet (10 mEq of sodium).
Note the depressor response and the progressive, dose-related in-
crease in mean renal blood flow (RBF).
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balance on a low salt diet: The increase showed a
close correlation with SQ 20881 dose (y = 4.05 log x
___________________
— 3.3; r = 0.66; P < .01) (Fig. 6). No change in
plasma renin activity occurred in patients on a high
salt intake.
A systematic change in the plasma bradykinin con-
centration after administration of SQ 20881 was not
demonstrated (Fig. 6). Plasma angiotensin II concen-
tration was more complicated, presumably because
of two simultaneous and diametrically opposite phe-
nomena. The blockade of conversion reduced plasma
angiotensin II concentration at a SQ 20881 dose of
30tg/kg (Fig. 6). Increasing SQ 20881 doses further
reduced the plasma angiotensin II concentration only
minimally, presumably because the progressive in-
crease in plasma renin activity was offsetting. The
concentration of plasma angiotensin II fell from a
control value of 39.6 4.3 pg/mI to 28,8 5.7 pg/mI
with a 30tg/kg SQ 20881 dose (P < 0.01). An ex-
cellent correlation was found between the control
angiotensin II concentration (x) and plasma Alt, 20
mm after a 30kg/kg SQ 20881 dose (y = 0.49x + 9.2;
r = 0.97; F 131; P << 0.01). An identical threshold
SQ 20881 dose induced a reduction in plasma anglo-
tensin II concentration, on the one hand, and a signif-
As with saralasin, blood pressure showed a dose-
related reduction after SQ 20881 in patients on a low
salt diet. The threshold dose was 30ig/kg, identical
to that for the renal blood flow increase (Fig. 4).
Blood pressure showed no systematic tendency to
change with time during the first 20 mm after admin-
istration.
The renal vascular response to SQ 20881 adminis-
tered into the renal artery in patients on a low salt
diet was significantly greater than after i.v. adminis-
tration (P < 0.005) (Fig. 5). Intraarterial administra-
tion did not alter blood pressure at l0g/kg. After
30tg/kg, blood pressure fell by 7 and 9 mm Hg in the
two individuals who received this dose, in the range
anticipated from i.v. infusion (Fig. 4).
Neither blood pressure nor renal blood flow was
modified systematically by SQ 20881 in the four pa-
tients on a high salt diet. Control renal blood flow
averaged 4.8 0.3 ml/g/min. In 16 studies with
doses of 30 and l00zg/kg, flow was reduced in nine,
with an insignificant average change of 0.06 0.19
ml/g/m in.
Saralasin had no systematic influence on plasma
renin activity at any dose, averaging 5.01 0.98
ng/ml/hr prior to saralasin, and 4.24 1.05
ng/ml/hr 20 mm after the agent was administered
(paired t = 1.22; P < 0.30). A dose-related increase in
plasma renin activity was apparent, however, within
20 mm after administration of SQ 20881 in patients in
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Fig. 5. Change in mean renal blood flow (MRBF) in response to
converting enzyme inhibition when SQ 20881 is given i.v. or into the
renal artery. The potentiated response to intraarterial injection
suggests that a critical locus of converting enzyme inhibition lies
within the kidney.
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Fig. 6. Changes in plasma renin activity (PRA), plasma angiotensin
11 concentration (All), and plasma bradykinin concentration with
increasing doses of SQ 20881. Note the progressive, dose-related
increase in PRA, the abrupt fall in plasma All concentration at
3Opg/kg, the threshold dose of SQ 20881 required to induce a
physiologic response, and the absence of a change in plasma
bradykinin concentration.
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icant change in arterial blood pressure and renal
blood flow, on the other.
In the three patients who were studied while on a
low salt diet, in whom blood samples were obtained
before and after a 30zg/kg SQ 20881 dose, renal
venous PRA increased strikingly following the agent,
plasma angiotensin II concentration in the renal vein
fell to the concentration found in the inflowing arte-
rial blood, and there was no systematic change in
renal venous plasma bradykinin concentration (Table
1).
Discussion
Haber has pointed out the key role that has been
played by surgical ablation in defining a hormone's
physiologic role [24]. In the case of the renin-angio-
tensin system, where the kidney is both the source of
the hormone and a major responding organ, this
approach is obviously impossible. For this reason,
the development of pharmacologic antagonists has
assumed special importance. Unfortunately, evidence
based primarily on pharmacologic assessment with a
blocking agent must be suspect, as few agents have a
single mechanism of action. As in earlier studies,
therefore, the rationale of our experimental design
was to employ two classes of agents with an unrelated
structure, a different locus of action, and probably
different secondary or side effects. Because of the
differences in their structure and mechanism of ac-
tion, it is reasonable to ascribe an identical physio-
logic response induced by saralasin and SQ 20881 to
their shared action—interruption of the renin-angio-
tensin system. This interpretation is strengthened if
the concomitant endocrine response supports the
conclusion: The threshold for a physiologic response
and the threshold for a reduction of plasma angioten-
sin II concentration with SQ 20881 was identical, and
plasma bradykinin was unaltered. The response to
saralasin occurred over a dose and time range which
was consistent with its known pharmacologic proper-
Table 1. Effect of SQ 20881 on arterial and renal venous hormone
concentrations
Artery(N=3)
Before After
Renal vein
(N=3)
Before After
PRA, ng of
Al/mi/hr 3.9 0.9 9.3 0.3 6.1 0.4 15.4 0.5
All,pg/mI 43 2 36 2 53 I 36 I
Bradykinin, ng/mi 3.8 0.3 5.8 2.1 7.5 1.2 7.7 + 0.9
Abbreviations used are PRA, plasma renin activity; Al, angio-
tensin 1; All, angiotensin II. N denotes the number of patients
used.
ties. These studies, therefore, assign the key role to
angiotensin as the mediator of the normal renal vas-
cular response to restriction of salt intake.
There are a few studies on the renal vascular re-
sponse to pharmacologic interruption of the renin-
angiotensin system in normal man. MacGregor and
Dawes [25] confirmed our finding of a reduction in
renal blood flow induced by saralasin in normal man
when the renin-angiotensin system was suppressed by
a high salt intake [23]. They denied, however, an
increase in renal blood flow in salt-depleted patients.
The lowest saralasin dose they used, however, was
250 ng/kg/min. In this study, saralasin increased
renal blood flow in patients on a low salt diet over
a narrow dose range, with a threshold of 10 ng/
kg/mm, and the largest increase occurred with 30
ng/kg/min in most patients. Thereafter, increasing
saralasin dosage led to a blood flow increase in some,
but in most a reduction occurred which paralleled
reduction of patients on a high salt intake. In general,
partial agonists display blockade at doses below the
level required to induce an agonist response [26].
Thus, the dose requirement is consistent with a renal
blood flow increase which reflects blockade of endog-
enous angiotensin II. The time course of the response
to the optimal saralasin dose when infused continu-
ously was also consistent with known pharmaco-
kinetics: saralasin has a half-life of approximately
three minutes in man [27]. Thus, one would antici-
pate reaching the maximal response in three to five
half-lives, or 10 to 15 mm, as was found.
The results were in accord with studies in the rabbit
and dog, where pharmacologic interruption provided
by angiotensin analogues, converting enzyme inhibi-
tion, or beta adrenergic blockade, increased renal
blood flow when the system was activated by re-
stricted sodium intake [12, 13, 17, 20].
Saralasin as an analogue of angiotensin H acts as a
competitive antagonist at the level of the angiotensin
receptor; not surprising in a structural analogue, this
agent is a partial agonist which displays angiotensin-
like activity in systems which are especially sensitive
to angiotensin [13, 23, 28]. Presumably, as an ex-
pression of this action, saralasin reduces renal blood
flow in normal man on a high salt intake [23], and in
this study an increasing dose resulted in a blood flow
reduction even in the patients in whom the renin-
angiotensin system had been activated by restriction
of sodium intake. There are a number of precedents
in which a peptide may act as primarily an agonist or
antagonist according to the experimental conditions
[28, 29]. This characteristic limits the utility of the
agent in assessing the role played by angiotensin H in
the pathogenesis of abnormal renal perfusion and
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function and in the agent's potential for therapy. The
optimal dose for a renal response to saralasin is likely
to vary with both the state of the renin-angiotensin
system and with the affinity of the angiotensin recep-
tor for angiotensin and saralasin—which may or may
not parallel the state of the renin-angiotensin system.
A positive renal response to saralasin is easily inter-
preted, but a negative response has little meaning
unless a full dose-response relationship has been es-
tablished. Perhaps further structural modification of
the molecule will result in agents which are pure
antagonists, where larger doses can be used.
SQ 20881 acts as an antagonist of both the enzy-
matic conversion of angiotensin I to the active octa-
peptide, angiotensin II, and also potentiates the re-
sponsiveness to bradykinin, because the same enzyme
is responsible for bradykinin degradation [30]. There
have been few systematic attempts to assess the rela-
tive effect of this agent on the kinin and renin-angio-
tensin systems. On the one hand, several observations
have suggested that SQ 20881 might have a larger
influence on plasma bradykinin. The Km for brady-
kinin is less than that for angiotensin 1 [30]. More-
over, the blockers potentiate the response to ex-
ogenous bradykinin at concentrations lower than
those required to block the conversion of angiotensin
I to angiotensin II [31]. On this basis several in-
vestigators have attributed the increased renal blood
flow induced by SQ 20881 in the anesthetized dog to a
local effect of increased bradykinin [32, 33]. SQ
20881, however, does not increase renal blood flow in
the dog or rabbit when the renin-angiotensin system
is suppressed by a high salt intake [13, 17, 20]; in-
deed, an as yet unexplained blood flow reduction
occurred. In this study SQ 20881 reduced plasma
angiotensin II concentration without influencing the
circulating bradykinin concentration in the dose
range over which the renal vasculature responded,
corroborating a small early experience [34—36]. The
influence of sodium intake on the renal response to
SQ 20881 and the close association between the dose
of SQ 20881 required to reduce plasma angiotensin II
concentration, on the one hand, and increase renal
blood flow, on the other, makes it very likely that SQ
20881 modified renal perfusion on the basis of inter-
ruption of the renin-angiotensin system.
The implications for renal function of the renal
vascular response to blockade were not defined in this
study, which was performed during arteriography.
Kimbrough et al [20] have recently reported that
both classes of agents not only increased renal blood
flow in the dog, but also induced a parallel increase in
glomerular filtration rate and sodium excretion when
the agents were administered into the renal artery,
thus avoiding the systemic effects. Earlier studies did
not reveal a similar functional response, but were
complicated by systemic administration of the agents,
and consequent hypotension [12, 13].
If the converting enzyme blockade responsible for
the renal blood flow increase was only in the lung,
one would have anticipated a maximal concentration
of the converting enzyme inhibitor at the critical
locus virtually instantaneously after i.v. injection. On
that basis, the maximum response would have been ex-
pected early, determined primarily by the half-life of
angiotensin II degradation or bradykinin build-up,
both of which are measurable in seconds [30]. The
largest part of the blood pressure and renal vascular
response was present by three minutes; a small but
significant progression of the renal vascular response
was also apparent. There were two possible explana-
tions for this phenomenon. The first was that con-
verting enzyme inhibition in the lung occurred more
slowly than might have been anticipated. The time
course of the systemic blood pressure response was
not consistent with this, as the depressor response
was complete within three minutes. The second possi-
bility was that for the renal vasculature a critical
locus of converting enzyme was not in the lung, but
rather in the kidney, where diffusion distances might
slow the time to peak effect of the converting enzyme
inhibitor. Certainly multiple lines of evidence suggest
that a quantitatively important converting enzyme is
present in the kidney, especially at a key site in the
juxtaglomerular apparatus [37—39]. SQ 20881 blocks
both isolated human lung and kidney converting
enzyme [40], and a recent report indicates that non-
pulmonary human vascular endothelium contains
converting enzyme which is blocked by SQ 20881 [41].
For these reasons, the response to the converting
enzyme inhibitor infused into the renal artery was
also assessed. The working hypothesis was that if the
critical concentration of enzyme was in the kidney,
intraarterial infusion would induce a potentiated re-
sponse, whereas if the critical converting enzyme was
in the lung, the response would either be unchanged
or reduced at any dose. A potentiated response to
intraarterial infusion suggested the former—that in
man a critical locus for the renal vascular response
was in the kidney.
Both pharmacologic agents, saralasin and SQ
20881, reduced blood pressure in the patients on a
low salt intake. The blood pressure reduction in the
patients on a low salt diet was small, but consistent,
and occurred with both agents despite the patients'
recumbent position. Moreover, neither agent reduced
blood pressure in patients studied on a high salt
intake. A similar blood pressure reduction during
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inhibition of converting enzyme was reported in nor-
mal man after restriction of salt intake, and was
potentiated when the patients were tilted to the up-
right position [25, 35, 42]. This observation suggests
that caution should be exercised in interpreting a
blood pressure fall in patients with hypertension, es-
pecially when they are on a severely restricted sodium
intake. A fall of up to 10 mm Hg is consistent with a
normal response, and does not indicate a contribu-
tion of angiotensin to the pathologic elevation of
pressure.
In conclusion, this study has defined multiple lines
of evidence which indicate that angiotensin plays an
important role in the renal vascular response to re-
striction of sodium intake in normal man. Restriction
of sodium intake is associated with a reduction in
renal blood flow, activation of the renin-angiotensin
system, and a striking reduction in the renal vascular
responsiveness to exogenous angiotensin II [11]. If
these are accepted as markers of angiotensin Ii's
playing a role in the renal vascular response, then the
results of this investigation provide the framework
necessary for examining the role of angiotensin in a
number of states characterized by these same stig-
mata, such as cirrhosis of the liver, congestive heart
failure, and the renal response to trauma.
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